Toronto General Hospital
Toronto, Ontario, M5G 1Z5, Canada
NCT Number: NCT01190059
The use of ex vivo lung perfusion (EVLP) will allow for a secondary evaluation technique for donor lungs that fail to meet standard acceptability criteria. This advanced assessment might lead to increased utilization rates of donor lungs and improved outcomes after lung transplantation.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 1
Toronto, Ontario, M5G 1Z5, Canada
Human donor lungs that do not meet the standard clinical criteria for donor lung utilization but fit into the study inclusion criteria will be retrieved from the donor using current donor lung retrieval techniques.
These lungs will be brought to the study transplant center to be re-assessed by the transplant team. The lungs will be physiologically assessed during ex vivo perfusion with Steen Solution. Perfusion of these lungs will be performed using Steen solution with the addition of methylprednisolone, heparin and antibiotics. With respect to the decision of lung utilization those organs with a delta pO2 (Δ pO2 = Pulmonary vein pO2 - pulmonary artery pO2) during ex vivo perfusion assessment > 350mmHg, good lung compliance, and a favorable opinion of the transplant surgeon will be considered transplantable. Lungs will be excluded for transplantation: if the Δ pO2 is less than 350mmHg or if they demonstrate >10% deterioration in any of the following functional parameters: pulmonary vascular resistance (PVR), dynamic compliance or airway pressures. Lungs will also be excluded if they are deemed unsuitable based on the clinical judgment of the lung transplant surgeon.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
for donor lung:
Exclusion criteria
The circuit is primed with 2,000cc Steen Solution™. At one hour of EVLP, 500 cc of circulated perfusate was removed and replenished with 500 cc of fresh perfusate. After that, 250 cc of perfusate was exchanged every hour.
Time frame: 72 hours
Immediate lung function is one of the key factors in determining the impact of donor lung quality, therefore the PGD score within 72 hrs was selected as the primary endpoint.
Time frame: 30 days
Mortality at 30 days post transplant
Time frame: 30 days
If the patient needed to be placed on extra-corporeal membrane oxygenation after transplantation.
Time frame: 30 days
To see if there was an increased risk for bronchial complications
Time frame: 30 days
How long was the patient on the ventilator after lung transplantation and was there an increased time on ventilator for the patient after EVLP.
Time frame: 30 days
Time frame: 30 days
Time in the hospital
XVIVO Perfusion
Industry
Acronym: HELP
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07716878
Bacterial Infections and Mycoses, Hematopoietic Stem Cell Transplantation (HSCT)
Guangzhou, Guangdong, China
View Trial DetailsNCT01294020
Heart Transplantation, Intestine Transplantation
Brussels, Belgium
View Trial DetailsNCT07660991
Lun Transplant Candidates, Lung Transplantation
Istanbul, Kartal, Turkey (Türkiye)
View Trial DetailsNCT07525440
Lung Transplantation
Guangzhou, China
View Trial Details